Hausstaubmilbe Dermatophagoides Farinae Hal Allergy

Hausstaubmilbe Dermatophagoides Farinae Hal Allergy is an allergen extract containing the Dermatophagoides farinae (house dust mite) protein, supplied in a cutaneous formulation for use in allergy immunotherapy. The product is marketed in the European Union and is intended to help modulate immune responses in individuals with documented sensitivity to Dermatophagoides farinae. It is an allergen extract for cutaneous administration in desensitization protocols.

Hausstaubmilbe Dermatophagoides Farinae Hal Allergy is indicated for individuals with confirmed allergic sensitivity to the house dust mite Dermatophagoides farinae.

- Adjunct to allergen-specific immunotherapy programs aimed at reducing clinical symptoms. - Use in skin testing to identify Dermatophagoides farinae sensitization. - Support for desensitization protocols in patients with mild to moderate allergic rhinitis. - Potential role in managing atopic dermatitis linked to dust‑mite allergy. - Integration into comprehensive allergy management plans under specialist supervision. - Facilitation of gradual exposure in controlled clinical settings to promote immunologic tolerance.

Local and systemic reactions may occur following cutaneous exposure to Dermatophagoides farinae extract; the frequency and severity vary among individuals.

Common: - Mild erythema or redness at the application site. - Transient itching or pruritus. - Localized swelling or edema. - Brief sensation of warmth or tingling. - Mild local pain or tenderness. - Temporary dry skin or scaling. - Slight increase in local temperature. - Mild headache. - Transient fatigue. - Slight nausea. - Occasional mild dizziness. - Temporary localized flushing. - Mild localized itching. - Slight skin discoloration.

Serious: - Severe urticaria or widespread hives. - Anaphylactic reaction requiring emergency medical attention. - Significant respiratory distress or bronchospasm. - Persistent angioedema affecting face or airway. - Severe systemic hypotension. - Cardiovascular collapse.

When using Hausstaubmilbe Dermatophagoides Farinae Hal Allergy, clinicians should evaluate patient history and monitor for adverse reactions to ensure safe application.

- Confirm documented Dermatophagoides farinae sensitization before initiation. - Avoid use in individuals with a history of severe anaphylaxis to dust‑mite extracts. - Conduct a supervised skin test prior to therapeutic dosing. - Monitor patients for at least 30 minutes after application for early signs of systemic reaction. - Pregnancy and lactation status should be assessed, as safety data are limited. - Store the product according to manufacturer instructions, protecting it from light and extreme temperatures. - Educate patients on recognizing and reporting any delayed or worsening symptoms.

Concurrent administration of other immunomodulatory agents may influence the safety profile of Dermatophagoides farinae extract; potential interactions should be reviewed before therapy.

Avoid: - Systemic antihistamines taken within 24 hours before skin testing, as they may suppress the test response. - High‑dose systemic corticosteroids, which can diminish immunologic reactivity. - Biologic agents such as omalizumab, which may modify IgE‑mediated responses.

Use with caution: - Topical corticosteroids applied near the test site, which may alter local skin response. - Beta‑blockers, due to possible attenuation of emergency treatment for severe reactions. - Immunotherapy agents targeting other allergens, requiring coordinated scheduling. - ACE inhibitors, as they may affect blood pressure regulation during systemic reactions. - Other immunomodulators that could alter immune response dynamics.